Delivery Order SPE2DB22D3010-SPE2DB25FP1YE
- Not listed
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $1,618.83 and a period of performance ending on March 6, 2025. It is a firm fixed-price contract and was not set aside for any specific...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $9,889.58 and a completion date of July 1, 2025. It is a firm fixed-price contract and is not set aside for any specific business type....
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $1,080.68 and is a firm fixed-price delivery order, with a period of performance ending on May 21, 2025. The contract is not set aside for...
- This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $2,384.55 and a period of performance through June 17, 2024. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) between...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Vyvanse 60 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed-price delivery order with a ceiling value of $1,399.56 and an ultimate completion date of September 19, 2024. This order is part of a larger Indefinite Delivery Contract...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 20 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $4,985.78 and a period of performance through April 2025. It is a firm-fixed-price contract, and there is no set-aside designation, indicating open...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Vyvanse 50 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $1,378.30 and a completion date of November 19, 2024. It is a firm-fixed-price contract, which means the price will not change...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,751.46, is for the supply of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is a firm-fixed-price delivery order, with a completion date of February 21, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $34,648.83 and a period of performance ending on June 24, 2025. The contract is a firm-fixed-price delivery order, indicating that the price is set...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $2,772.55 and is a Firm Fixed Price, non-set-aside award with a performance period through June 17, 2025. Amerisourcebergen Drug Corp is...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP1YEDelivery Order
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Vyvanse 40 mg capsules, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has a ceiling value of $3,182.94 and an ultimate completion date of March 19, 2025. It is a firm-fixed-price contract, which means the price will not change regardless of the contractor's actual costs. The contract is not set aside for any specific business type. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 3/18/25 |